X

On July 3, 2020 Sanofi Genzyme was notified that our Lemtrada Home Phlebotomy Partner, Examination Management Services Inc., (EMSI) has gone out of business. Because of this, unfortunately, all future Lemtrada Home Phlebotomy (lab draw) visits from EMSI have been cancelled. Patient safety is Sanofi Genzyme’s #1 priority and we are working to provide an alternative phlebotomy solution as well as coordinate alternative testing options for your next monthly lab tests. If you have any questions related to this announcement, please contact your healthcare provider or your One to One Nurse at 1-855-557-2483.

MAT-US-2015317

LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

LEMTRADA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.

Have you been considering discussing your relapsing MS treatment options with your healthcare provider? Find information, inspiration, and support to start a conversation about LEMTRADA, an infusion treatment for relapsing MS.

LEMTRADA dosing schedule

THE LEMTRADA DOSING
SCHEDULE

Learn about how LEMTRADA is given in yearly treatment rounds.

LEMTRADA study data

THE LEMTRADA CLINICAL
STUDIES

See how LEMTRADA was studied to assess relapses and disability.

LEMTRADA resources

FIND MORE LEMTRADA
RESOURCES

Download resources for patients and support partners.

Important Safety Information See More

LEMTRADA can cause serious side effects including serious autoimmune problems. Some people receiving LEMTRADA develop a condition where the immune cells in your body attack other cells or organs in the body (autoimmunity), which can be serious and may cause death. Serious autoimmune problems may include: